Surveillance of Antimicrobial Consumption

In Primary Care

2026 Quarter 1

Key Points


  • The rate of antimicrobial consumption in primary care in Ireland for the first quarter (Q1) of 2026 was 20.9 defined daily doses (DDD) per 1,000 inhabitants per day (DID). This represents a decrease compared with the same period last year, when consumption was 21.6 DID. It is the lowest level recorded for Q1 in the past 10 years, excluding the pandemic years.

  • Tetracyclines showed a reduction in consumption between 2024 and 2025, decreasing from 4.2 DID in 2024 to 4.1 DID in 2025. However, consumption increased again in Q1 of 2026. The consumption of this group was recorded at 4.9 DID in Q1, the highest level ever recorded for a single quarter to date. That said, when comparing Q1 of 2025 and Q1 of 2026 at the individual tetracycline level, there was a minor decrease in doxycycline consumption, from 3.6 DID to 3.5 DID. Meanwhile, consumption of lymecycline and minocycline increased. Lymecycline consumption rose from 0.78 DID to 1.08 DID.

  • The consumption of penicillins decreased between Q1 of 2025 and Q1 of 2026, falling from 10.6 DID to 9.5 DID. This is the lowest recorded level for penicillins in Q1 in the past 10 years, excluding the pandemic years. The decrease in this group was driven by reductions in several antimicrobial agents. Consumption of amoxicillin, the amoxicillin–clavulanic acid combination, and flucloxacillin declined between these two quarters, while consumption of the remaining penicillins remained relatively stable.

  • The consumption of cephalosporins did not change between Q1 of 2025 and Q1 of 2026, remaining at 1.1 DID in both quarters. However, analysis at the ATC level 5 showed an increase in cefalexin consumption, while consumption of cefuroxime and cefaclor decreased. This indicates a shift from second-generation to first-generation cephalosporin use.

  • Consumption of all other agents was relatively stable between Q1 of 2025 and Q1 of 2026, with the exception of methenamine. Although methenamine is coded under J01 (antibacterials for systemic use), it is primarily used as an antiseptic for urinary tract infections. A significant increase in methenamine consumption was observed; however, this is thought to be due to sales data not being accurately captured prior to Q4 of 2025. This increase was also the primary driver of the rise observed in the J01X (other antibacterials) group.


Methodology

Background

Antimicrobial consumption is the main driver of antimicrobial resistance. Therefore, antimicrobial consumption surveillance is important to identify potential over and inappropriate use of antimicrobial agents.

ATC/DDD Methodology

Irish antimicrobial sales data are obtained from IQVIA (formerly IMS Health), a pharmaceutical market research company. This dataset contains regional, monthly wholesaler-to-community pharmacy sales data from over 95% of the wholesalers and manufacturers in Ireland.

Consumption is measured as defined daily dose (DDD), which is the assumed average maintenance dose per day for a drug used for its main indication in adults. The WHO Anatomical Therapeutic Chemical (ATC) index is used to categorise antimicrobial agents. The ATC/DDD system is recommended by WHO as the international standard for drug utilization studies and it serves as a tool for drug utilization monitoring and research to improve quality of drug use. More information on ATC/DDD Methodology can be found on WHO’s website.

Consumption rates are calculated as DDD per 1000 inhabitants per day (DID). Eurostat yearly population estimates are used for national rates. Central Statistics Office 2022 Census results are proportionated with Eurostat population to calculate the county rates. The underlying trend on the quarterly graph is derived by using local regression of seasonal results.

The WHO introduced the AWaRe classification in 2017 as part of its Essential Medicines List to support antimicrobial stewardship activities. This system categorizes antibiotics into three groups—Access, Watch, and Reserve—to promote their responsible use. To assess the relative consumption of these categories, the 2025 AWaRe classification is applied. By 2030, the EU aims for at least 65% of total antibiotic consumption to come from the Access group in every Member State.

The European Surveillance of Antimicrobial Consumption Network (ESAC-Net) is managed by the European Centre for Disease Prevention and Control (ECDC) and the network uses the same methodology. The country rates for the EU Member States are obtained from ECDC’s ESAC-Net Dashboard. More information on ESAC-Net can be found on ECDC’s website.

Limitations

Although the IQVA database used in this report is very comprehensive, there are some limitations. The data are based on pharmacy wholesale data, rather than on individual prescriptions. Thus, it cannot be used to determine the actual number of antimicrobial courses taken and does not provide information on dose or duration of therapy. Factors such as stockpiling of antimicrobials in pharmacies and drug wastage (e.g. passing the sell-by date) may introduce biases. Likewise, recent changes to prescribing guidelines, that recommend using higher doses may lead to an increase in consumption (as measured by DDD/1000 inhabitants/day), while the total number of prescriptions may have remained static or even declined.


Main Results



Table 1: Antibiotic Consumption in the Last 5 Years by ATC-3 Groups

ATC-3 Name

2022

2023

2024

2025

2026

J01A Tetracyclines

3.8

3.9

4.2

4.1

4.9

J01C Beta-Lactam Antibacterials, Penicillins

10.4

10.5

10.4

9.8

9.5

J01D Other Beta-Lactam Antibacterials

1.3

0.5

0.8

1.1

1.1

J01E Sulfonamides and Trimethoprim

0.8

0.9

0.8

0.8

0.8

J01F Macrolides, Lincosamides and Streptogramins

3.4

3.1

3.3

3.0

3.1

J01M Quinolone Antibacterials

0.4

0.4

0.3

0.3

0.3

J01X Other Antibacterials

1.4

1.3

1.2

1.2

1.4

Total Consumption

21.5

20.6

21.0

20.2

20.9





Seasonal (Quarterly) Results



Table 2: Quarterly (Seasonal) Consumption of Antibiotics in the Last 5 Years

Year

Q1

Q2

Q3

Q4

Rate

2022

18.7

19.9

18.2

29.1

21.4

2023

21.2

19.1

19.0

23.2

20.6

2024

21.6

20.1

19.2

23.3

21.0

2025

21.6

18.6

17.5

23.0

20.2

2026

20.9

20.9



Tetracyclines



Table 3: Consumption of Tetracyclines (J01A) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

3.8

3.8

3.1

4.6

2023

4.0

3.6

3.7

4.4

2024

4.4

4.2

3.7

4.5

2025

4.5

3.8

3.5

4.5

2026

4.9


Penicillins



Table 4: Consumption of Penicillins (J01C) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

8.3

9.2

8.7

15.2

2023

10.7

9.5

9.5

12.4

2024

10.8

9.8

9.0

12.0

2025

10.6

8.9

8.2

11.5

2026

9.5


Other Beta-Lactams



Table 5: Consumption of Other Beta-Lactams (J01D) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

1.1

1.2

1.1

1.9

2023

0.5

0.5

0.5

0.5

2024

0.6

0.6

0.9

1.1

2025

1.1

1.0

1.0

1.2

2026

1.1


Macrolides



Table 6: Consumption of Macrolides (J01F) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

2.9

3.2

2.8

4.6

2023

3.3

3.0

2.8

3.3

2024

3.2

3.3

3.2

3.4

2025

3.2

2.7

2.6

3.4

2026

3.1


Quinolones



Table 7: Consumption of Quinolones (J01M) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

0.4

0.4

0.4

0.4

2023

0.4

0.4

0.3

0.4

2024

0.4

0.3

0.3

0.3

2025

0.3

0.3

0.3

0.3

2026

0.3


Results by Counties





Tetracyclines



Penicillins



Other Beta-Lactams



Macrolides



Quinolones



Results by CHOs and RHAs


Table 8: Overall Antibiotic Consumption in the Latest Year by CHO Areas

CHO Area

LHO Area

Q1

Q2

Q3

Q4

Rate

1

Donegal LHO, Sligo/Leitrim/West Cavan LHO and Cavan/Monaghan LHO

22.0

22.0

2

Galway LHO, Roscommon LHO and Mayo LHO

21.8

21.8

3

Clare LHO, Limerick LHO and North Tipperary/East Limerick LHO

24.6

24.6

4

Kerry LHO, North Cork LHO, North Lee LHO, South Lee LHO and West Cork LHO

22.6

22.6

5

South Tipperary LHO, Carlow/Kilkenny LHO, Waterford LHO and Wexford LHO

23.1

23.1

6

Wicklow LHO, Dún Laoghaire LHO and Dublin South East LHO

23.5

23.5

7

Kildare/West Wicklow LHO, Dublin West LHO, Dublin South City LHO and Dublin South West LHO

17.8

17.8

8

Laois/Offaly LHO, Longford/Westmeath LHO, Louth LHO and Meath LHO

21.4

21.4

9

Dublin North LHO, Dublin North Central LHO and Dublin North West LHO

18.1

18.1


Table 9: Overall Antibiotic Consumption in the Latest Year by RHAs

RHA

HSE Area

Q1

Q2

Q3

Q4

Rate

Area A

HSE Dublin & NE

19.2

19.2

Area B

HSE Dublin & Midlands

19.7

19.7

Area C

HSE Dublin & SE

22.9

22.9

Area D

HSE SW

22.6

22.6

Area E

HSE MW

24.6

24.6

Area F

HSE W & NW

21.8

21.8

Monthly Comparison


Tetracyclines



Penicillins



Other Beta-Lactams



Macrolides



Quinolones



International Comparison